Immutrin is a biotechnology company developing next generation antibody therapy to deplete systemic amyloid deposits and reverse amyloidosis.

The Company’s lead asset is being developed for the treatment of ATTR cardiomyopathy, a serious and progressive form of amyloidosis. Immutrin's antibody is a potential best-in-class therapy, with a unique mechanism of action designed to selectively and exclusively remove established amyloid fibrils.

Immutrin

The Cambridge office likely focuses on financial oversight and strategic planning, supporting the organization's financial health.

Cambridge

Mihriban Tuna

This department focuses on innovating and improving products through scientific research and experimentation.

Immutrin

Org chart

Teams

Research and Development

Offices

Immutrin

Org chart

Teams

Research and Development

Offices

Related companies